🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Pfizer to conduct trials of antiviral COVID-19 pill in Russia

Published 16/11/2021, 08:57
© Reuters. FILE PHOTO: A syringe and vial are seen in front of a displayed Pfizer logo in this illustration taken June 24, 2021. REUTERS/Dado Ruvic
PFE
-

(Refiles to remove typo in first paragraph)

MOSCOW (Reuters) -Russia has granted approval for Pfizer Inc (NYSE:PFE) to conduct clinical trials in Russia of its experimental antiviral pill to treat COVID-19, a state registry of medicines showed on Tuesday.

The trials conducted on 90 people located in home-like conditions with someone who has symptomatic COVID-19 began on Nov. 12 and will continue until March 2023, the registry's website said.

© Reuters. FILE PHOTO: A syringe and vial are seen in front of a displayed Pfizer logo in this illustration taken June 24, 2021. REUTERS/Dado Ruvic

Pfizer said earlier this month the experimental antiviral pill cut by 89% the chance of hospitalisation or death for adults at risk of severe disease. It hopes to make the pill available globally as quickly as possible.

The pill has the brand name Paxlovid.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.